ProMetic Life Sciences (PLI) Stock Price, News & Analysis

Company Overview

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$13.60 to C$13.60
• 52-Week Range: N/A
• Volume: 921 shs
• Average Volume: 8,002 shs
• Market Capitalization: C$317.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PLI Stock Analysis - Frequently Asked Questions

How do I buy shares of ProMetic Life Sciences?

Shares of PLI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of ProMetic Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProMetic Life Sciences investors own include Nemaska Lithium (NMX), Crescent Point Energy (CPG), ProMetic Life Sciences (PFSCF), Bombardier, Inc. Class B (BBD.B), Sierra Wireless (SWIR), Baytex Energy (BTE) and Dollarama (DOL).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:PLI
• CUSIP: N/A
• CIK: N/A
• Web: prometic.com
• Phone: +1-450-7810115
• Fax: N/A
• Employees: 487
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 37.47
• Current Ratio: 4.06
• Quick Ratio: 3.66

Sales & Book Value

• Annual Sales: C$39.91 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.94
• Book Value: C$6.07 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 23,313,000
• Free Float: N/A
• Market Cap: C$317.06 million
• Optionable: Not Optionable
• Beta: N/A